LH02
General Information
DRACP ID DRACP01784
Peptide Name LH02
Sequence RRRRRRRRVKLVNLGFATLREHVP
Sequence Length 24
UniProt ID Q06234 Q02067 P19359 P50553
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
NCI-H82 | Lung small cell carcinoma; Small cell lung cancer | Carcinoma | EC50≈7 μM | MTT assay | Not available | Patent |
NCI-H187 | Lung small cell carcinoma; Small cell lung cancer | Carcinoma | EC50≈10 μM | MTT assay | Not available | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C131H233N55O29
Absent amino acids CDIMQSWY
Common amino acids R
Mass 345304
Pl 13.05
Basic residues 11
Acidic residues 1
Hydrophobic residues 8
Net charge 10
Boman Index -12790
Hydrophobicity -119.58
Aliphatic Index 89.17
Half Life
Mammalian: 1 hour
Yeast: 2 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US2020/0157150A1
Patent Title Anticancer Peptides
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017
Other Published ID AU2018311129A1 CA3071601A1 CN111436200A EP3661947A1 JP2020529429A KR20200032730A WO2019025432A1